The simplest health insurance pitch is also the most expensive to deliver: pay one monthly premium, get your checkup, and never see another bill. Curative has built a $1.275 billion valuation on the bet that this model, which flips the standard incentive from avoiding care to seeking it, can be run profitably [Business Wire, Dec 2025]. The Austin-based insurer, which pivoted from COVID-19 testing, now tells employers it will cover 165,000 people with a plan that has $0 copays, $0 deductibles, and $0 out-of-pocket costs for in-network care,provided members complete an annual baseline visit [LinkedIn News, 2025] [curative.com/about-us]. It is a radical simplification of the consumer experience, and a massive actuarial gamble that preventive engagement will curb downstream costs.
The wedge is a checkup
The core product is a trade. In exchange for a comprehensive annual visit,which 98% of members complete within 120 days, according to the company,Curative removes all financial friction for in-network care for the rest of the year [Healthcare Brew, Mar 2026]. For an employee, it means no surprise $40 copay for a specialist or $1,000 deductible to meet before coverage kicks in. For Curative, the baseline visit is a data-gathering and relationship-forming event that allows its clinical teams to identify and manage health risks early. The company describes an "AI-powered member experience" to guide care, but the fundamental economic lever is behavioral: make the first visit easy and free, hoping it reduces the likelihood and cost of a later, catastrophic one [Business Wire, Dec 2025].
A pivot funded for scale
Curative’s path to this model was unconventional. Founded in 2020 with an initial focus on sepsis diagnostics, it pivoted hard into COVID-19 testing, scaling to 35 million tests before exiting that business [LinkedIn, 2026]. The operational tempo and regulatory navigation from that period now underpin its insurance rollout. The recent $150 million Series B, led by investors including SoftBank Vision Fund and Justin Mateen’s JAMS, values the company at $1.275 billion and is earmarked for geographic and membership growth [Business Wire, Dec 2025]. Leadership blends scientific and financial rigor, with co-founder Fred Turner’s background in biotech diagnostics paired with President and CFO Tami Wilson-Ciranna’s experience [Forbes, 2017] [LinkedIn, 2026].
| Role | Name | Notable Background |
|---|---|---|
| CEO & Co-founder | Fred Turner | Previously founded Shield Bio; co-founded TL Biolabs [Forbes, 2017]. |
| President & CFO | Tami Wilson-Ciranna | Financial leadership; joined alongside co-founders [LinkedIn, 2026]. |
| Co-founder | Isaac Turner | Technical co-founder from inception. |
| Chief Scientific Officer & Co-founder | Vlad Slepnev | Scientific co-founder [Crunchbase, 2026]. |
The actuarial counter-bet
The model’s obvious risk is adverse selection. The promise of zero out-of-pocket costs could disproportionately attract employees who know they will need expensive care, potentially creating a risk pool that is costlier than the premiums collected. Curative’s defense rests on a few key controls:
- The baseline gate. The required visit acts as a mild filter and a massive data collection point.
- Employer size. Plans are for employers with 51+ employees, relying on the natural risk distribution of a workforce rather than individuals [Wikipedia].
- Network steering. The "$0" promise only applies to in-network care, giving Curative significant use to direct members to contracted, value-based providers. The company claims it is on track for $570 million in revenue this year, which suggests premium income is scaling rapidly, but the ultimate proof will be in medical loss ratios over time [LinkedIn News, 2025]. Competitors like Centivo and Sana Benefits also focus on value-based, employer-sponsored plans, but none anchor their entire value proposition on the complete elimination of member cost-sharing after a single visit.
The unit economics of prevention
The back-of-the-envelope math is compelling, if it holds. Assume a member’ baseline visit costs Curative $500. If that visit identifies and manages a condition that would have led to a $50,000 hospitalization later, the return on that preventive investment is 100x, not counting the human benefit. The company’s entire bet is that its engagement model can find enough of those avertable crises to offset the increased utilization its $0 promise will inevitably drive. It’s a bet on the power of aligned incentives. If it works, Curative isn’t just another insurer, it’s a managed care organization that finally figured out how to make money by keeping people healthy. The incumbent it must beat isn’t a specific company, but the entire industry’s deeply ingrained skepticism that you can remove financial barriers without bankrupting the plan.
Sources
- [Business Wire, Dec 2025] Curative Raises $150 Million in Series B Funding | https://www.businesswire.com/news/home/20251202857803/en/Curative-Raises-$150-Million-in-Series-B-Funding-to-Redefine-the-Future-of-Health-Insurance
- [LinkedIn News, 2025] Health insurance startup Curative raises $150M | https://www.linkedin.com/news/story/health-insurance-startup-curative-raises-150m-6787620/
- [curative.com/about-us] About Our Health Care | Curative | https://curative.com/about-us
- [Healthcare Brew, Mar 2026] Curative CEO Fred Turner explains why his alternative health plan is valued at $1.3b | https://www.healthcare-brew.com/stories/2026/03/20/curative-ceo-fred-turner-alternative-health-plan
- [LinkedIn, 2026] Hasan Kavak - Curative | LinkedIn | https://www.linkedin.com/in/hasankavak/
- [Forbes, 2017] TL Biolabs | https://www.forbes.com/profile/tl-biolabs/
- [LinkedIn, 2026] Tami Wilson-Ciranna - President & CFO at Curative Inc. | https://www.linkedin.com/in/tami-wilson-ciranna-1785474/
- [Wikipedia] Curative (company) - Wikipedia | https://en.wikipedia.org/wiki/Curative_(company)
- [Crunchbase, 2026] Vlad Slepnev - Crunchbase | https://www.crunchbase.com/person/vlad-slepnev